ABVC BioPharma, Inc.
ABVCAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Maxim Group | downgrade | Buy →Hold | Nov 16, 2022 |
Earnings History
Next report: Nov 16, 2026 · EPS est. $-0.40| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 12, 2026 | $-0.03 | $-0.40 | — | $113.3K |
| May 18, 2026 | $-0.06 | — | — | — |
| Mar 3, 2026 | $-0.12 | — | -$796.0K | — |
| Oct 31, 2025 | $-0.05 | $-0.40 | — | $300.0K |
| Aug 13, 2025 | $-0.13 | $-0.60 | — | $300.0K |
| Apr 30, 2025 | $0.04 | $-0.50 | — | $300.0K |
| Mar 11, 2025 | $0.02 | $-1.50 | $2.0K | $26.4K |
| Nov 14, 2024 | $-0.02 | $-2.00 | $389.3K | $26.2K |
News
JERSEY CITY, N.J., Nov. 2, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that ABVC BioPharma, Inc. ("ABVC" or the "Company") (NASDAQ: ABVC), has closed a private placement of original issue discount senior convertible promissory notes ("OID Notes") pursuant to a securities purchase agreement with institutional and other accredited investors, generating aggregate gross proceeds of approximately $3.39 million, be…
ABVC BioPharma (NASDAQ: ABVC - Get Free Report) and Takeda Pharmaceutical (NYSE: TAK - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, profitability and institutional ownership. Risk and Volatility ABVC BioPharma has a beta